1 Title

- 2 A deep intronic variant in *MME* causes autosomal recessive Charcot-Marie-Tooth neuropathy
- 3 through aberrant splicing.

4 Authors

- 5 Bianca R Grosz^{1,2}, Jevin M Parmar^{3,4}, Melina Ellis^{1,2}, Samantha Bryen^{5,6}, Cas Simons^{5,6},
- 6 Andre L.M. Reis^{5,7,8}, Igor Stevanovski^{5,7}, Ira W. Deveson^{5,7,8}, Garth Nicholson^{2,11}, Nigel
- 7 Laing³, Mathew Wallis^{9,10}, Gianina Ravenscroft³, Kishore R. Kumar^{2,11,12,13}, Steve Vucic^{2,14},
- 8 Marina L Kennerson^{1,2,11}
- 9 ORCID:
- 10 Bianca R Grosz: 0000-0002-6926-0551
- 11 Jevin Parmar: 0000-0003-1864-8094
- 12 Melina Ellis: 0000-0002-8542-048X
- 13 Samantha Bryen: 0000-0002-4140-8622
- 14 Cas Simons: 0000-0003-3147-8042
- 15 Andre L.M Reis: 0000-0002-7300-1157
- 16 Igor Stevanovski: 0000-0002-7713-1979
- 17 Ira W Deveson: 0000-0003-3861-0472
- 18 Mathew Wallis: 0000-0002-5441-1732
- 19 Garth A Nicholson: 0000-0001-9694-066X
- 20 Nigel Laing: 0000-0001-5111-3732

- 21 Gianina Ravenscroft: 0000-0003-3634-211X
- 22 Kishore R Kumar: 0000-0003-3482-6962
- 23 Marina L Kennerson: 0000-0003-3332-5074
- 24
- 25 Affiliations:

26	1.	Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139,
27		Australia
28	2.	The University of Sydney, Camperdown, NSW, 2050, Australia
29	3.	Rare Disease Genetics and Functional Genomics Research Group, Harry Perkins
30		Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia,
31		6009, Australia
32	4.	Centre for Medical Research, Faculty of Health and Medical Sciences, The University
33		of Western Australia, Perth, WA 6009, Australia
34	5.	Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW
35		Sydney, Sydney, NSW, Australia
36	6.	Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne,
37		VIC, Australia
38	7.	Genomics and Inherited Disease Program, Garvan Institute of Medical Research,
39		Sydney, NSW, Australia.
40	8.	Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
41	9.	Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS,
42		Australia.
43	10.	School of Medicine and Menzies Institute for Medical Research, University of
44		Tasmania, Hobart, TAS, Australia.
45	11.	Molecular Medicine Laboratory and Neurology Department, Concord Repatriation
46		General Hospital, Hospital Rd, Concord, NSW, 2139, Australia
47	12.	Translational Neurogenomics Group, Genomic and Inherited Disease Program, The
48		Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010,
49		Australia
50	13.	St Vincent's Healthcare Campus, Faculty of Medicine, UNSW Sydney, Level 5, De
51		Lacy Building, St Vincent's Hospital, Darlinghurst, NSW, 2010, Australia.
52	14.	Brain and Nerve Research Centre, The University of Sydney, Sydney, NSW 2139,
53		Australia
54		
55		

57 Abstract

58	Background: Loss-of-function variants in MME (membrane metalloendopeptidase) are a
59	known cause of recessive Charcot-Marie-Tooth Neuropathy (CMT). A deep intronic variant,
60	MME c.1188+428A>G (NM_000902.5), was identified through whole genome sequencing
61	(WGS) of two Australian families with recessive inheritance of axonal CMT using the seqr
62	platform. MME c.1188+428A>G was detected in a homozygous state in Family 1, and in a
63	compound heterozygous state with a known pathogenic MME variant (c.467del;
64	p.Pro156Leufs*14) in Family 2.
CE.	Aims: We simed to determine the nethogenicity of the MME $a 1188 \pm 428$ A>C variant

Aims: We aimed to determine the pathogenicity of the *MME* c.1188+428A>G variant
through segregation and splicing analysis.

67 Methods: The splicing impact of the deep intronic *MME* variant c.1188+428A>G was
68 assessed using an *in vitro* exon-trapping assay.

Results: The exon-trapping assay demonstrated that the *MME* c.1188+428A>G variant created a novel splice donor site resulting in the inclusion of an 83 bp pseudoexon between *MME* exons 12 and 13. The incorporation of the pseudoexon into *MME* transcript is predicted to lead to a coding frameshift and premature termination codon (PTC) in *MME* exon 14 (p.Ala397ProfsTer47). This PTC is likely to result in nonsense mediated decay (NMD) of *MME* transcript leading to a pathogenic loss-of-function.

Interpretation: To our knowledge, this is the first report of a pathogenic deep intronic *MME* variant causing CMT. This is of significance as deep intronic variants are missed using whole exome sequencing screening methods. Individuals with CMT should be reassessed for deep intronic variants, with splicing impacts being considered in relation to the potential pathogenicity of variants.

80 Key Words (up to 5): Charcot-Marie-Tooth disease, splicing, *MME*, recessive, deep intronic

81 Introduction

82 Charcot-Marie-Tooth neuropathy (CMT) is the most common inherited peripheral neuropathy, affecting 1/2500 individuals^{1.} CMT is characterized by progressive length-83 84 dependent loss of peripheral motor and sensory nerves, resulting in distal muscle weakness and sensory symptoms². Patients are broadly divided into subtypes based on whether nerve 85 86 conduction studies (NCS) indicating demyelinating (CMT1) or axonal (CMT2) forms of the 87 disease. Recessive loss-of-function variants in the membrane metalloendopeptidase (MME) 88 gene have been previously reported to cause axonal Charcot-Marie-Tooth neuropathy type 2T (CMT2T; OMIM: #617017)³⁻¹¹. MME encodes for neprilysin, a widely expressed membrane-89 bound metallopeptidase that has a key role in neuropeptide processing¹². A significant portion 90 of patients with axonal CMT remain genetically undiagnosed^{13–17}, indicating that further 91 92 disease-causing genes and pathogenic variants in known genes are yet to be identified.

Splicing variants are increasingly being recognized as a cause of Mendelian disease^{18,19}. The 93 94 precise removal of introns (non-coding regions) and inclusion of exons (coding regions) in 95 the final mature mRNA relies on the spliceosome and auxiliary splicing factors recognizing 96 specific sequence motifs, such as the 5' donor splice site and 3' acceptor splice site. Splice-97 altering variants can weaken or abolish recognition of the correct splice sites, or alternatively strengthen or create cryptic splice sites that mimic consensus splicing sequences²⁰. These 98 99 variants typically lead to one or more mis-splicing events that result in the skipping of partial or complete exons, and/or the retention of partial or complete introns ²¹⁻⁴². Pathogenic 100 splicing variants have been found in several CMT genes including $MPZ^{21,30,39,40}$, 101 MFN2^{22,30,31}, LRSAM1²³, IGHMBP2²⁴, INF2²⁵, MCM3AP²⁶, SH3TC2^{30,32,38}, GDAP1^{27,42}, 102 $SBF1^{28}$, $NDRG1^{37}$, and $FGD4^{29}$. Variants affecting canonical splice donor and acceptor sites 103 have also been described in $MME^{4,41}$. 104

105 Exon-trapping, also known as a mini-gene assay, is an *in vitro* technique used to identify exons in a genomic region of interest 43 . This is of particular use when relevant patient tissue 106 is unavailable or when relevant transcripts may be unstable or degraded by nonsense 107 mediated decay (NMD)⁴⁴. The genomic region of interest is cloned into an exon-trapping 108 109 vector between two known exons. This exon-trapping vector is transfected into a cell line 110 where it is transcribed and undergoes a series of post-transcriptional processes that include 111 pre-mRNA splicing to create mature mRNA. This mRNA consists of the 'trapped' exons of 112 the genomic region of interest flanked by the known exons, which can then be Sanger 113 sequenced to characterize the 'trapped' exons. Comparison of 'trapped' exons between wild type and variant genomic sequences can also indicate if a candidate variant affects splicing 4^{4-1} 114 ⁵¹. The well-validated exon-trapping vector pSpliceExpress ⁵² consists of known exons of the 115 116 rat insulin gene, *Ins2*, and has been used previously to determine the splicing impacts of multiple pathogenic variants in Mendelian disease 45-51. 117

118 Here we report a deep intronic variant in MME [chr3:155142758A>G (hg38); MME 119 c.1188+428A>G], found in a recessive state in two Australian families. Exon-trapping 120 revealed that this variant creates a novel splice donor site in *MME* intron 12 (NM_000902.5) 121 which, along with a preceding existing cryptic splice acceptor site, results in the 122 incorporation of an 83 bp pseudoexon in the MME transcript [chr3:155,142,675-155,142,757 123 (hg38); r.1188_1189ins[1188+345_1188+427]]. The coding frameshift caused by this 124 pseudoexon leads to a PTC in exon 14 and likely NMD of the MME transcript 125 (p.Ala397ProfsTer47), resulting in a loss of *MME* function.

127 Materials and Methods:

128 Subjects

Members of Family 1 were recruited and informed consent was obtained for this study using protocols approved by the Sydney Local Health District Human Ethics Research Committee (2019/ETH07839). Recruitment and informed consent for the proband of Family 2 was approved by the Human Research Ethics Committee of the Royal Melbourne Hospital (HREC/16/MH/251).

134 Variant Detection

Genomic DNA for Family 1 was extracted from peripheral blood using the PureGene Kit (Qiagen) following the manufacturer's instructions. WGS for two individuals in Family 1 (V:1 and V:3) was outsourced to the Garvan Sequencing Platform. Paired-end sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing machine, with 30-fold average read depth.

In Family 2, genomic DNA for the proband was extracted at the Department of Diagnostic Genomics (PathWest, Perth, Australia) using the QIAsymphony^{SP} machine and QIAsymphone® DSP DNA Midi Kit. The proband underwent WGS at the Australian Genomics Research Facility (AGRF), Melbourne, following GATK4 best-practices. Pairedend sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing machine, with 30-fold average read depth. Parental DNA was not available for sequencing.

WGS data processing was performed at the Centre for Population Genomics (CPG) following the DRAGEN GATK best practices pipeline. Reads were aligned to the hg38 reference genome using Dragmap (v1.3.0). Cohort-wide joint calling of single nucleotide variants (SNVs) and small insertion/deletion (indel) variants was performed using GATK

151 HaplotypeCaller (v4.2.6.1) with "--dragen-mode" enabled. Sample sex and relatedness quality checks were performed using Somalier $(v0.2.15)^{53}$. Variants were annotated using 152 VEP 105, and loaded into the web-based variant filtration platform, seqr⁵⁴. A WGS search 153 was conducted using the seqr⁴⁵ platform for low minor allele frequency (<0.01) variants in 154 155 CMT-related genes. for both Family 1 and 2 gene list-Hereditary Neuropathy_CMT_IsolatedAndComplex (Version 2.14)⁵⁵]. Additionally, variants were 156 CPG Automated 157 analyzed by the Interpretation Pipeline (AIP, 158 https://github.com/populationgenomics/automated-interpretation-pipeline). In silico splicing analysis was conducted using SpliceAI⁵⁶. 159

160 Segregation Analysis

161 The MME c.1188+428A>G variant in Family 1 and Family 2 was amplified using primers 162 MME 12 (5'-CTCAGCCGAACCTACAAGGA-3'; that spanned intron 5'-GCAAATGCTGCTTCCACAT-3') to produce a 1264 bp amplicon [chr3:155,142,289-163 164 155,143,552 (hg38)]. An internal sequencing primer was used (5'-165 CTGTGTTAAAAGTAATTTCGGGGG-3') and the amplicon was Sanger sequenced. The MME c.467del variant in Family 2 was amplified (5'-GCAGAGCCGTATGCATCACT-3'; 166 167 5'-TTCAGCTGTCCAAGAAGCACC-3'). А 717bp amplicon produced was [chr3:155,116,171-155,116,887 (hg38)], which was subsequently Sanger sequenced. 168

169

170 Sanger Sequencing

171 For Family 1, PCR amplicons were sent to Garvan Molecular Genetics, Garvan Institute

172 (Sydney, Australia) for Sanger sequencing using BigDye Terminator cycle sequencing

173 protocols. For Family 2, proband PCR amplicons were Sanger sequenced at AGRF, Perth

- using BigDye Terminator sequencing protocols. Sequences were visualized and analyzed
- using Snapgene Software version 7.1 (www.snapgene.com).

|--|

177 Oxford Nanopore Technologies (ONT) Long Read Sequencing

High molecular weight (HMW) DNA samples of the Proband in Family 2 were transferred to
the Garvan Sequencing Platform for targeted long-read sequencing analysis on ONT
instruments. Prior to ONT library preparations, DNA was sheared to ~20-25 kb fragment size
using a MegaRuptor 3 instrument and visualized post-shearing on an Agilent FemtoPulse.

182 Sequencing libraries were prepared from \sim 3-5 µg of HMW DNA, using native library prep 183 kit SQK-LSK114, according to manufacturer's instructions. Each library was loaded onto a 184 R10.4.1 flow cell and sequenced on a PromethION device with live target selection/rejection executed by the ReadFish software package⁵⁷. Detailed descriptions of software and hardware 185 configurations used for ReadFish are provided in a previous publication⁵⁸. Samples were run 186 187 for a maximum duration of 72 h, with nuclease flushes and library reloading performed at 188 approximately 24- and 48-h timepoints for targeted sequencing runs, to maximize sequencing yield. Raw ONT sequencing data was converted to BLOW5 format⁵⁹ using slow5tools 189 (v.0.3.0)⁶⁰ then base-called using Guppy (v6). Resulting FASTQ files were aligned to the 190 hg38 reference genome using minimap2 (v2.14-r883)⁶¹. Variants were called using clair3⁶², 191 192 phased using Whatshap⁶³ and visualized using the Integrative Genomics Viewer (IGV, $v2.17.3)^{64}$. 193

194 Cell Culture

195 The human HeLa cervical epithelial cell line (ATCC) was maintained in Dulbecco's 196 Modified Eagle's Medium (DMEM)(Gibco) containing 10% (v/v) fetal bovine serum (FBS) 197 (Gibco), +100 U/mL penicillin (Gibco), and 100 μ g/mL streptomycin (Gibco) at 37°C in 198 humidified air and 5% CO2.

199 Cloning Procedures

200 The region surrounding *MME* c.1188+428A>G [chr3:155,141,790-155,143,755 (hg38)] was 201 amplified from the genomic DNA of a heterozygous carrier of the c.1188+428A>G variant, 202 using attB adapter primers (5'-AAAAAGCAGGCTTCGCTCTTAAATGGTTGGCTT-3'; 5'-203 AGAAAGCTGGGTAACTAGACTCTTGGGGGAAGGC -3'). The MME amplicon was then 204 cloned into the exon-trapping pSpliceExpress vector between flanking *Ins2* exons using a 205 two-step Gateway cloning BP reaction (ThermoFisher). pSpliceExpress was a gift from Stefan Stamm (Addgene plasmid #32485)⁵². The pSpliceExpress-MME clones were then 206 207 Sanger sequenced to verify the correct insertion of MME and to determine the 208 c.1188+428A>G genotype of each clone (as the genomic DNA template was heterozygous 209 for the variant).

210 In vitro exon-trapping

211 HeLa cells were grown to approximately 70% confluence in a 6-well plate. HeLa cells were 212 separately transfected with either 2 μ g of pSpliceExpress-*MME*_{WT} or 2 μ g of pSpliceExpress-213 MME_{c.1188+428A>G} using Lipofectamine 3000 (ThermoFisher). RNA extraction was performed 214 48 h following transfection using the RNEasy Mini Kit (Qiagen), and reverse-transcribed 215 template was prepared using the iScript cDNA Synthesis Kit (Bio-Rad). PCR amplification 216 of cDNA was conducted using primers designed to anneal to the flanking Ins2 exons (5'-217 CAGCACCTTTGTGGTTCTCA-3'; 5'-CAGTGCCAAGGTCTGAAGGT-3'). The RT-PCR 218 amplicons were size fractionated using a 1.5% w/v agarose gel. The largest amplicon for each 219 vector was gel-purified using Isolate II PCR and Gel Kit (Bioline) for Sanger Sequencing.

220 In silico splicing analysis of reported MME variants

All reported *MME* variants in gnomAD v.4.0.0 were detected by searching the gnomAD browser for the genomic region corresponding with the *MME* gene; '3-155024124-155183704'(hg38). The *MME* variants reported in gnomAD were then exported using the

224 'Export Variants to CSV' function. The consequences of the variants were descri	bed t	рy
---	-------	----

- 225 gnomAD using the Variant Effect Predictor (VEP) annotation based on the most deleterious
- 226 predicted functional effect of each variant ⁶⁵. These variants were then filtered for a minor
- 227 allele frequency (MAF) <0.01 and a maximum SpliceAI ∆score >0.8 (high precision splicing
- 228 change prediction⁶⁶) as annotated by gnomAD.
- 229
- 230

232 **Results**:

233 Clinical Phenotypes

234 Family 1 consists of four affected siblings from a consanguineous family of European (non-235 Finnish) background (Figure 1a). The phenotype was consistent with a generalized 236 sensorimotor axonal neuropathy and sensory ataxia without cerebellar signs (Table 1), and 237 was confirmed with NCS for individuals V:1 and V:6 (Table 2). Affected individuals had 238 previously undergone diagnostic and research whole exome sequencing with negative results. 239 Family 2 consists of one affected female born to a healthy, non-consanguineous couple 240 (Figure 1b). Neurological examination revealed mild distal upper limb weakness and 241 moderate distal lower limb weakness (Table 1). NCS showed evidence of an axonal 242 sensorimotor neuropathy (Table 2). Bilateral MRI of the thighs and calves showed muscle 243 atrophy (Supplementary Figure 1).

244 Genetic Analysis

245 WGS screening using the seqr platform in Family 1 revealed a single homozygous variant in 246 two affected individuals (V:1 and V:3), MME c.1188+428A>G (NM_000902.5). This variant was reported in dbSNP build 155^{67} (rs61758195), with a low MAF in gnomAD v4.0.0⁶⁸ 247 (10/152120), All of Us (35/490,748)⁶⁹, and TOPMED⁷⁰ (15/264290). No homozygous 248 249 individuals were reported in gnomAD, All of Us, or TOPMED. SpliceAI predicted that MME 250 c.1188+428A>G could create a strong novel splice donor site (Score 0.97; where a SpliceAI 251 score above 0.8 is considered a 'high precision' predicted splice variant⁵⁶). This in turn 252 strengthened the SpliceAI prediction for a cryptic splice acceptor site 83 bp upstream of the 253 novel splice donor site (Score 0.99).

Segregation analysis in Family 1 confirmed the biallelic inheritance of the *MME* c.1188+428A>G variant segregated with the CMT phenotype (Figure 1a). Sanger sequencing of DNA from available individuals showed that all affected individuals were homozygous for the *MME* c.1188+428A>G variant and unaffected individuals were carriers (Supplementary Figure 2).

259 WGS screening using the seqr platform and AIP was conducted in the proband of Family 2 260 (II:1). The MME c.1188+428A>G variant was detected in a compound heterozygous state 261 with a second MME variant (MME c.467del; p.Pro156Leufs*14), which has previously been reported as pathogenic⁴¹ (Figure 1b). Sanger sequencing validated the presence of each *MME* 262 263 variant in the index individual (Supplementary Figure 3). As parental DNA was unavailable, 264 ONT long-read sequencing was conducted to phase the heterozygous MME variants in the 265 proband (Figure 1c-d). ONT long-read sequencing confirmed that MME c.1188+428A>G 266 (boxed red in Figure 1c) and c.467del (boxed red in Figure 1d) were present on alternative 267 haplotypes (hap-1: red, hap-2: blue) and therefore were in *trans* in the proband.

268 In vitro exon-trapping of MME-pSpliceExpress vectors

269 Two separate exon-trapping pSpliceExpress vectors were generated to assess the in vitro 270 splicing impact of the MME c.1188+428A>G variant: pSpliceExpress-MME_{WT} (wild-type) 271 and pSpliceExpress- $MME_{c,1188+428A>G}$ (variant). A schematic of the constructs and relevant 272 SpliceAI scores are shown in Figure 2a. RT-PCR products produced following transfection of 273 these vectors were analyzed using gel electrophoresis (Figure 2b), which revealed a visible 274 size difference between the wild-type (381 bp) and MME c.1188+428A>G amplicons (464 275 bp). The gel-purified amplicons were Sanger sequenced and the sequencing was aligned to 276 the WT MME mRNA sequence. The sequenced products showed that the pSpliceExpress-277 MME_{WT} produced a transcript that was correctly spliced between MME exon 12 and 13 278 (Figure 2c). In contrast, exon-trapping of the pSpliceExpress- $MME_{c,1188+428A>G}$ vector showed 279 that an 83 bp pseudoexon had been spliced between MME exon 12 and 13 (Figure 2d). A BLAT search⁷¹ using the sequence of the trapped pseudoexon revealed alignment to the 280 281 intronic region directly upstream of the MME c.1188+428A>G variant [chr3:155,142,675-282 155,142,757 (hg38)]. This suggests that the MME c.1188+428A>G variant creates a novel 283 splice donor site leading to the aberrant inclusion of 83 bp of intronic *MME* sequence in the 284 final spliced transcript, as predicted by SpliceAI. Prediction of the novel MME coding 285 sequence caused by the introduction of the pseudoexon showed that a PTC was generated in 286 exon 14 (p.Ala397ProfsTer47) at genomic position chr3:155,144,368 (hg38)(Supplementary 287 Figure 4). This PTC likely leads to NMD of the *MME* transcript.

288 In silico splicing analysis of MME variants

All reported *MME* variants in gnomAD v.4.0.0 were assessed using the integrated SpliceAI scores to determine if splicing variants in *MME* were a likely underrecognized cause of disease. There were 37,264 total variants reported in *MME* in gnomAD, of which 35,673 variants had a MAF <0.01. Of these, 88 variants had a maximum SpliceAI Δ score above 0.8

293 (Supplementary Table 1). There were no homozygotes reported for any of the 88 MME 294 putative splicing variants. The majority of these predicted splicing variants were predicted to 295 directly change either the canonical splice donor sites (26/88) or canonical splice acceptor 296 sites (30/88) of MME, including an inframe deletion (c.1317_1317+2del) and a frameshift 297 variant (c.957+1del). An additional nine variants were predicted to affect a splicing region, 298 including one which is also annotated as a synonymous variant (c.1188G>A; p.Lys396Lys). 299 Nine missense variants (p.Asp209Gly, p.Ile217Ser, p.Glu282Val, p.Arg365Ile, p.Ser436Gly, 300 p.Asp533Gly, p.Ile553Val, p.Val554Phe, p.Gln692Arg) and a synonymous variant 301 (p.Glv417Glv) were also predicted to alter splicing. Twelve variants were annotated as 302 'intron variants', of which two could be considered 'deep intronic' variants 303 (c.1188+428A>G, described in this manuscript, and c.197-9871A>G). Interestingly, further 304 analysis using SpliceAI demonstrated that MME c.197-9871A>G was predicted to create a 305 splice donor site (Score 0.81) and strengthen an upstream cryptic splice acceptor site (Score 306 (0.81) in a similar manner to c.1188+428A>G, thereby possibly creating an in-frame 96 bp 307 pseudoexon.

308

310 Discussion

311 Here we report a deep intronic variant, MME c.1188+428A>G causing recessive CMT2T in 312 two unrelated Australian families. This variant results in a pseudoexon that likely leads to 313 NMD of the MME transcript, resulting in a loss-of-function. This is in keeping with 314 previously reported MME variants which have broadly been characterised as 'loss-of-315 function' variants. To our knowledge, this is the first report of a pathogenic deep intronic 316 variant in MME. Given that a significant portion of patients with axonal CMT remain genetically undiagnosed¹³⁻¹⁷, it's possible that deep intronic variants in *MME* explain a 317 318 portion of this diagnostic gap.

319 Individuals from Family 1 previously underwent both diagnostic WES and research WES, 320 and the proband in Family 2 previously underwent targeted gene panel testing (PathWest 321 neuro v3). These testing methods did not capture deep intronic regions and returned negative 322 results. However, deep intronic regions have previously been shown to have a higher prevalence of variants than coding regions and canonical splice sites⁷². Our findings suggest 323 324 that intronic SNPs should be analyzed to determine if they impact splicing before they are 325 dismissed as benign. Detection and functional validation of deep intronic variants has 326 previously been shown to increase diagnostic rates in other Mendelian diseases including Xlinked Alport syndrome⁷³, inherited retinal disorders^{74,75}, and dystrophinopathy^{76,77}. 327 328 Pathogenic deep intronic variants, such as described here, are likely to be underreported 329 amongst CMT-causing genes due to a lack of detection by WES and targeted gene panels, 330 and a lack of functional investigation upon detection.

The *MME* c.1188+428A>G variant was reported in multiple different genetic ancestry groups
 in gnomAD v.4.0.0⁶⁸, including in the European (Non-Finnish) (8/68008), African/African

333 American (1/41432), and 'remaining' (1/2092) ancestry groups. This was also reflected in the 'All of Us' Research Program⁶⁹, which reported the MME c.1188+428A>G variant in the 334 335 African (2/107,888) and European populations (33/256,804). Whilst it is possible that MME 336 c.1188+428A>G represents a recurrent *de novo* variant, it is also likely that this variant has 337 persisted at low levels in the global population. As this variant is missed by WES and may 338 not be prioritised by variant-filtering approaches focusing on coding variants, this variant 339 may therefore represent an underappreciated cause of recessive CMT. This is further 340 supported by its detection in two Australian CMT families who are not known to be related.

341 Whilst the predicted splicing variants reported in MME are individually rare, we have 342 described eighty-eight variants in gnomAD that are predicted by SpliceAI to alter splicing. 343 Nine of these variants were annotated as missense variants, and one was a synonymous 344 change. This is of note as these 'missense' variants are often assumed to result in a single 345 amino acid change, and synonymous variants are often considered functionally neutral, with their effect on splicing typically not assessed⁷⁸. Our results suggest that the discovery of any 346 347 of these eighty-eight variants in a homozygous or compound heterozygous state in an 348 individual with CMT should prompt further functional investigation of their effect on splicing 349 of the MME transcript.

Prior to functional validation, *MME* c.1188+428A>G was considered a variant of uncertain significance (VUS) according to American College of Medical Genetics and Genomics (ACMG) criteria⁷⁹ (BP4, PM2, PM3, PP1), However, the functional evidence generated by the splicing assay now allows for the addition of PVS1 (null variant in a gene where loss-offunction is a known mechanism of disease) and PS3 (well-established *in vitro* or *in vivo* functional studies supportive of a damaging effect on the gene or gene product) criteria. This allows reclassification of the variant as 'pathogenic'. Therefore, this work demonstrates the

importance of functional validation to confirm the effect of candidate variants on splicing toincrease diagnostic rates for those with inherited disease.

359 Previously described homozygous *MME* patients typically have a phenotype consistent with 360 late-onset axonal neuropathy. In contrast, three of the four affected siblings in Family 1 361 described childhood onset and the proband of Family 2 described symptom onset in early 362 adulthood. It has also previously been reported that heterozygous MME variants can cause spinocerebellar ataxia type 43 (SCA43)⁸⁰ as well as autosomal dominant CMT³. However, 363 364 the individuals in Family 1 who were MME c.1188+428A>G heterozygotes were all 365 clinically assessed as neurologically normal, including an individual who is in their seventh 366 decade. Homozygous affected individuals in Family 1 were noted to have a sensory ataxia 367 rather than cerebellar ataxia, although MRI brain studies were not conducted. Therefore, our 368 findings here do not support a role for MME c.1188+428A>G to cause SCA43 or autosomal 369 dominant CMT, and further expand the phenotype of recessive CMT2T.

370 Understanding the specific effects of splice-affecting variants is crucial for developing 371 potential therapeutic strategies. Antisense oligonucleotides (ASOs) that modulate splicing are 372 an active area of research, including individualized approaches to treat rare genetic diseases^{81–83}. Several antisense nucleotides that modify splicing have been approved by the 373 374 United States Food and Drug Administration and have resulted in marked improvements in clinical outcomes in those with genetic diseases⁸⁴⁻⁹⁴. An FDA-approved "n-of-1" ASO, 375 376 milasen, successfully blocked pathogenic pseudoexon inclusion in MFSD8 in a patient with neuronal ceroid lipofuscinosis type 7^{94} . ASOs which block pathogenic pseudoexons, such as 377 378 that created by MME c.1188+428A>G, have also been described in *in vivo* preclinical models^{93,95-99}. As such, individuals with the MME c.1188+428A>G variant may represent a 379

form of CMT that is treatable through personalized ASO therapy and warrants furtherinvestigation.

382

383 Acknowledgements

- 384 This work was funded by the Medical Research Future Fund (MRFF) Genomics Health
- Futures Mission (APP2007681). JMP is supported by the Australian Government Research
- Training Program. IWD was supported by MRF2025138 & MRF2023126. Genomic analysis
- 387 was supported by the Centre for Population Genomics (Garvan Institute of Medical Research
- and Murdoch Children's Research Institute) and was funded in part by a National Health and
- 389 Medical Research Council investigator grant (2009982) and the Medical Research Future
- 390 Fund (MRFF) Genomics Health Futures Mission (2008820).

391 Figure Legends:

392 Figure 1: The MME c.1188+428A>G (NM_000902.5) variant segregates with recessive 393 **CMT in two families.** A) Family 1 pedigree showing the associated genotypes for the *MME* 394 c.1188+428A>G (NM_000902.5) variant. Affected individuals in the fifth generation are 395 homozygous (G/G). Unaffected individuals in the fifth (V) and sixth (VI) generation are 396 heterozygous (A/G). Squares represent males and circles represent females, solid symbol 397 denotes affected individual. The double line in the fourth (IV) generation indicates a 398 consanguineous relationship. The MME c.1188+428 genotype is denoted beneath individuals 399 who underwent Sanger sequencing, with the pathogenic 'G' allele in red text. B) A pedigree 400 showing the associated genotypes for MME c.1188+428A>G and MME c.467del in the index 401 individual in Family 2. C-D) Haplotype phasing showed that the c.1188+428A>G (C) and 402 c.467del (D) variants were present on alternative haplotypes (light red and light blue), thus 403 inherited in trans in the proband of Family 2. Phased targeted ONT long-read sequencing 404 reads were visualized using the Integrative Genomics Viewer (IGV; v2.17.3).

405 Figure 2. An exon-trapping assay was used to analyze splicing changes caused by the 406 *MME* c.1188+428A>G variant. A) Schematic of the pSpliceExpress-*MME*_{WT} (wild-type) 407 and pSpliceExpress- $MME_{c.1188+428A>G}$ (variant) constructs. Both constructs consisted of an 408 RSV LTR promoter region (blue) controlling transcription of a minigene of MME exons 12 409 and 13 (grey) flanked by Ins2 exon 2 and Ins2 exon 3 (black). The constructs differed in the 410 presence of either an A (wild type: green text) or a G allele (mutant: red text) at MME 411 c.1188+428A>G. i) The wild type sequence was not predicted to contain any strong splice 412 sites when assessed using SpliceAI, with a score of 0.11 for the acceptor site (purple text) and 413 0.00 for the donor site (green text). ii) SpliceAI predicted that the MME c.1188+428A>G 414 variant (red arrow) would create a strong splice donor site [Score: 0.97 (Δ 0.97); red text], 415 which then strengthened the prediction of a splice acceptor site 83 bp upstream [Score 0.99]

416 $(\Delta 0.97)$; purple text]. The predicted 83 bp pseudoexon sequence is capitalized and boxed in 417 red. B) The amplicon produced by the pSpliceExpress- $MME_{c,1188+428A>G}$ vector (464 bp) 418 showed a visible increase in product size when compared to the amplicon produced by 419 pSpliceExpress- MME_{WT} (381 bp). The 158 bp RT-PCR product produced by both vectors indicated splicing and ligation of the flanking Ins2 exon 2 and exon 3. Lanes: L: 420 421 HyperLadder 100 bp (Bioline); WT: wild-type; NRTC: negative cDNA conversion control 422 (no reverse transcriptase). NTC: negative PCR reaction control (no cDNA template). C) 423 Sanger sequencing of the pSpliceExpress-MME_{WT} RT-PCR product confirmed correct 424 splicing between MME exon 12 and 13. D) Sanger sequencing of the pSpliceExpress-425 $MME_{c.1188+428A>G}$ RT-PCR product revealed the presence of a novel 83 bp pseudoexon (red) 426 between MME exon 12 and 13. Abbreviations: RSV LTR: Rous Sarcoma Virus Long 427 Terminal Repeat promoter; *Ins2*: rat preproinsulin 2 gene.

428

430 References

- Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. *Clin Genet*.
 1974;6:98-118.
- 434 2. Szigeti K, Lupski JR. Charcot–Marie–Tooth disease. *European Journal of Human*435 *Genetics*. 2009;17(6):703-710. doi:10.1038/ejhg.2009.31
- 436 3. Senderek J, Lassuthova P, Kabzińska D, et al. The genetic landscape of axonal
 437 neuropathies in the middle-aged and elderly. *Neurology*. 2020;95(24).
 438 doi:10.1212/WNL.000000000011132
- 4. Higuchi Y. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth
 disease type 2. *Ann Neurol*. 2016;79:659-672.
- 441 5. Record CJ, Pipis M, Skorupinska M, et al. Whole genome sequencing increases the
 442 diagnostic rate in Charcot-Marie-Tooth disease. *Brain*. Published online March 14,
 443 2024. doi:10.1093/brain/awae064
- 444 6. Jamiri Z, Khosravi R, Heidari MM, Kiani E, Gharechahi J. A nonsense mutation in
 445 <a href="https://www.scps.com/cscpscheats-com/cs
- Taghizadeh S, Vazehan R, Beheshtian M, et al. Molecular Diagnosis of Hereditary
 Neuropathies by Whole Exome Sequencing and Expanding the Phenotype Spectrum. *Arch Iran Med.* 2020;23(7):426-433. doi:10.34172/AIM.2020.39
- Ando M, Higuchi Y, Yuan J, et al. Comprehensive Genetic Analyses of Inherited
 Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. *Biomedicines*.
 2022;10(7):1546. doi:10.3390/biomedicines10071546
- Megarbane A, Bizzari S, Deepthi A, et al. A 20-year Clinical and Genetic
 Neuromuscular Cohort Analysis in Lebanon: An International Effort. *J Neuromuscul Dis*. 2022;9(1):193-210. doi:10.3233/JND-210652
- Høyer H, Hilmarsen HT, Sunder-Plassmann R, et al. A polymorphic AT-repeat causes
 frequent allele dropout for an *MME* mutational hotspot exon. *J Med Genet*.
 2022;59(10):1024-1026. doi:10.1136/jmedgenet-2021-108281
- 11. Dupuis M, Raymackers JM, Ackermans N, Boulanger S, Verellen-Dumoulin C.
 Hereditary axonal neuropathy related to MME gene mutation in a family with
 fetomaternal alloimmune glomerulonephritis. *Acta Neurol Belg*. 2020;120(1):149-154.
 doi:10.1007/s13760-020-01275-9
- Krämer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic
 inflammation in mice deficient of neutral endopeptidase. *Neurobiol Dis*.
 2009;35(2):177-183. doi:10.1016/j.nbd.2008.11.002

467 468 469	13.	Gemelli C, Geroldi A, Massucco S, et al. Genetic Workup for Charcot-Marie-Tooth Neuropathy: A Retrospective Single-Site Experience Covering 15 Years. <i>Life (Basel)</i> . 2022;12(3). doi:10.3390/life12030402
470 471 472 473	14.	Candayan A, Parman Y, Battaloğlu E. Clinical and Genetic Survey for Charcot-Marie- Tooth Neuropathy Based on the Findings in Turkey, a Country with a High Rate of Consanguineous Marriages. <i>Balkan Med J</i> . 2022;39(1):3. doi:10.4274/BALKANMEDJ.GALENOS.2021.2021-11-13
474 475 476	15.	Rudnik-Schöneborn S, Tölle D, Senderek J, et al. Diagnostic algorithms in Charcot- Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. <i>Clin Genet</i> . 2016;89(1):34-43. doi:10.1111/cge.12594
477 478 479	16.	Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. 2015;86(8):873-878. doi:10.1136/jnnp-2014-308826
480 481 482	17.	Ma Y, Duan X, Liu X, Fan D. Clinical and mutational spectrum of paediatric Charcot- Marie-Tooth disease in a large cohort of Chinese patients. <i>Front Genet</i> . 2023;14. doi:10.3389/fgene.2023.1188361
483 484	18.	Lord J, Baralle D. Splicing in the Diagnosis of Rare Disease: Advances and Challenges. <i>Front Genet</i> . 2021;12:689892. doi:10.3389/fgene.2021.689892
485 486 487	19.	Wang R, Helbig I, Edmondson AC, Lin L, Xing Y. Splicing defects in rare diseases: transcriptomics and machine learning strategies towards genetic diagnosis. <i>Brief Bioinform</i> . 2023;24(5). doi:10.1093/bib/bbad284
488 489 490	20.	Anna A, Monika G. Splicing Mutations in Human Genetic Disorders: Examples, Detection, and Confirmation. Vol 59. Springer Verlag; 2018:253-268. doi:10.1007/s13353-018-0444-7
491 492 493	21.	Corrado L, Magri S, Bagarotti A, et al. A novel synonymous mutation in the MPZ gene causing an aberrant splicing pattern and Charcot-Marie-Tooth disease type 1b. <i>Neuromuscular Disorders</i> . 2016;26(8):516-520. doi:10.1016/j.nmd.2016.05.011
494 495 496	22.	Boaretto F, Vettori A, Casarin A, et al. Severe CMT type 2 with fatal encephalopathy associated with a novel MFN2 splicing mutation. <i>Neurology</i> . 2010;74(23). doi:10.1212/WNL.0b013e3181e240f9
497 498 499	23.	Engeholm M, Sekler J, Schöndorf DC, et al. A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance. <i>BMC Neurol</i> . 2014;14(1):118. doi:10.1186/1471-2377-14-118
500 501 502 503	24.	Cassini TA, Duncan L, Rives LC, et al. Whole genome sequencing reveals novel <i>IGHMBP2</i> variant leading to unique cryptic splice \Box site and Charcot \Box Marie \Box Tooth phenotype with early onset symptoms. <i>Mol Genet Genomic Med</i> . 2019;7(6):e00676. doi:10.1002/mgg3.676
504 505	25.	Echaniz Laguna A, Latour P, Echaniz-Laguna A, Latour P, Echaniz Laguna A, Latour P. A cryptic splicing mutation in the INF2 gene causing Charcot-Marie-Tooth

506 507		disease with minimal glomerular dysfunction. <i>Journal of the Peripheral Nervous System</i> . 2019;24(1):120-124. doi:10.1111/jns.12308
508 509 510	26.	Ylikallio E, Woldegebriel R, Tumiati M, et al. MCM3AP in recessive Charcot-Marie- Tooth neuropathy and mild intellectual disability. <i>Brain</i> . 2017;140(8):2093-2103. doi:10.1093/brain/awx138
511 512 513 514	27.	Numakura C, Lin C, Ikegami T, Guldberg P, Hayasaka K. Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations. <i>Hum Mutat</i> . 2002;20(5):392-398. doi:10.1002/humu.10134
515 516 517	28.	Flusser H, Halperin D, Kadir R, Shorer Z, Shelef I, Birk OS. Novel SBF1 splice-site null mutation broadens the clinical spectrum of Charcot-Marie-Tooth type 4B3 disease. <i>Clin Genet</i> . 2018;94(5):473-479. doi:10.1111/cge.13419
518 519 520	29.	Hayashi M, Abe A, Murakami T, et al. Molecular analysis of the genes causing recessive demyelinating Charcot-Marie-Tooth disease in Japan. <i>J Hum Genet</i> . 2013;58(5):273-278. doi:10.1038/jhg.2013.15
521 522 523	30.	DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot- Marie-Tooth disease in over 17,000 individuals with neuropathy. <i>Mol Genet Genomic</i> <i>Med</i> . 2014;2(6):522-529. doi:10.1002/mgg3.106
524 525 526	31.	Martikainen MH, Kytövuori L, Majamaa K. Novel mitofusin 2 splice-site mutation causes Charcot–Marie–Tooth disease type 2 with prominent sensory dysfunction. <i>Neuromuscular Disorders</i> . 2014;24(4):360-364. doi:10.1016/J.NMD.2014.01.007
527 528 529	32.	Piscosquito G, Saveri P, Magri S, et al. Screening for SH3TC2 gene mutations in a series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4). <i>J Peripher Nerv Syst.</i> 2016;21(3):142-149. doi:10.1111/jns.12175
530 531 532	33.	Benedetti S, Previtali SC, Coviello S, et al. Analyzing histopathological features of rare Charcot-Marie-Tooth neuropathies to unravel their pathogenesis. <i>Arch Neurol</i> . 2010;67(12):1498-1505. doi:10.1001/archneurol.2010.303
533 534 535	34.	Li MY, Yin M, Yang L, et al. A novel splicing mutation in 5'UTR of GJB1 causes X- linked Charcot—Marie–tooth disease. <i>Mol Genet Genomic Med.</i> 2023;11(3):e2108. doi:10.1002/MGG3.2108
536 537 538	35.	Boso F, Taioli F, Cabrini I, Cavallaro T, Fabrizi GM. Aberrant Splicing in GJB1 and the Relevance of 5' UTR in CMTX1 Pathogenesis. <i>Brain Sci.</i> 2020;11(1):24. doi:10.3390/brainsci11010024
539 540 541	36.	Tomaselli PJPPJ, Rossor AM, Horga A, et al. Mutations in noncoding regions in GJB1 are a major cause of X-linked CMT. <i>Neurology</i> . 2017;88(15):1445-1453. doi:10.1212/WNL.00000000003819
542 543 544	37.	Pravinbabu P, Holla V V, Phulpagar P, et al. A splice altering variant in NDRG1 gene causes Charcot-Marie-Tooth disease, type 4D. <i>Neurol Sci.</i> 2022;43(7):4463-4472. doi:10.1007/s10072-022-05893-4

545 546 547 548	38.	Shchagina O, Orlova M, Murtazina A, Filatova A, Skoblov M, Dadali E. Evaluation of Pathogenicity and Causativity of Variants in the MPZ and SH3TC2 Genes in a Family Case of Hereditary Peripheral Neuropathy. <i>Int J Mol Sci.</i> 2023;24(12). doi:10.3390/ijms24129786
549 550 551	39.	Taioli F, Cabrini I, Cavallaro T, Simonati A, Testi S, Fabrizi GM. Déjerine-Sottas syndrome with a silent nucleotide change of myelin protein zero gene. <i>Journal of the Peripheral Nervous System</i> . 2011;16(1):59-64. doi:10.1111/j.1529-8027.2011.00319.x
552 553 554	40.	Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B. <i>Neurology</i> . 2006;67(7):1141-1146. doi:10.1212/01.wnl.0000238499.37764.b1
555 556 557	41.	Lupo V. Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying MME mutations. <i>J Med Genet</i> . 2018;55:814-823.
558 559 560 561	42.	Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P, Stojkovic T. WES homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy reveals intronic GDAP1 variant leading to a premature stop codon. <i>Neurogenetics</i> . 2018;19(2):67-76. doi:10.1007/s10048-018-0539-7
562 563 564 565	43.	Duyk GM, Kim SW, Myers RM, Cox DR. Exon trapping: a genetic screen to identify candidate transcribed sequences in cloned mammalian genomic DNA. <i>Proceedings of the National Academy of Sciences</i> . 1990;87(22):8995-8999. doi:10.1073/pnas.87.22.8995
566 567 568 569	44.	Micale L, Morlino S, Schirizzi A, et al. Exon-Trapping Assay Improves Clinical Interpretation of COL11A1 and COL11A2 Intronic Variants in Stickler Syndrome Type 2 and Otospondylomegaepiphyseal Dysplasia. <i>Genes (Basel)</i> . 2020;11(12):1513. doi:10.3390/genes11121513
570 571 572	45.	Grosz BR, Tisch S, Tchan MC, et al. A novel synonymous KMT2B variant in a patient with dystonia causes aberrant splicing. <i>Mol Genet Genomic Med</i> . 2022;10(5). doi:10.1002/MGG3.1923
573 574 575	46.	Mutai H, Wasano K, Momozawa Y, et al. Variants encoding a restricted carboxy- terminal domain of SLC12A2 cause hereditary hearing loss in humans. <i>PLoS Genet</i> . 2020;16(4). doi:10.1371/journal.pgen.1008643
576 577 578	47.	Knapp KM, Sullivan R, Murray J, et al. Linked-read genome sequencing identifies biallelic pathogenic variants in DONSON as a novel cause of Meier-Gorlin syndrome. <i>J Med Genet</i> . 2020;57(3):195-202. doi:10.1136/jmedgenet-2019-106396
579 580 581	48.	Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase-α regulates the activation of type i interferons through cytosolic RNA:DNA synthesis. <i>Nat Immunol</i> . 2016;17(5):495-504. doi:10.1038/ni.3409
582 583 584	49.	Varga L, Danis D, Skopkova M, et al. Novel EYA4 variant in Slovak family with late onset autosomal dominant hearing loss: A case report. <i>BMC Med Genet</i> . 2019;20(1). doi:10.1186/s12881-019-0806-y

585 586 587 588	50.	Legendre M, Rodriguez-Ballesteros M, Rossi M, et al. CHARGE syndrome: A recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and minigene assays /631/208 /692/308 brief-communication. <i>European Journal of Human Genetics</i> . 2018;26(2):287-292. doi:10.1038/s41431-017-0007-0
589 590 591	51.	Abdulhay NJ, Fiorini C, Verboon JM, et al. Impaired human hematopoiesis due to a cryptic intronic GATA1 splicing mutation. <i>Journal of Experimental Medicine</i> . 2019;216(5):1050-1060. doi:10.1084/jem.20181625
592 593	52.	Kishore S, Khanna A, Stamm S. Rapid generation of splicing reporters with pSpliceExpress. <i>Gene</i> . 2008;427(1-2):104-110. doi:10.1016/j.gene.2008.09.021
594 595 596	53.	Pedersen BS, Bhetariya PJ, Brown J, et al. Somalier: rapid relatedness estimation for cancer and germline studies using efficient genome sketches. <i>Genome Med</i> . 2020;12(1):62. doi:10.1186/s13073-020-00761-2
597 598 599	54.	Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool for rare disease genomics. <i>Hum Mutat</i> . 2022;43(6):698-707. doi:10.1002/HUMU.24366
600 601 602	55.	Stark Z, Foulger RE, Williams E, et al. Scaling national and international improvement in virtual gene panel curation via a collaborative approach to discordance resolution. <i>Am J Hum Genet</i> . 2021;108(9):1551-1557. doi:10.1016/j.ajhg.2021.06.020
603 604 605	56.	Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. <i>Cell</i> . 2019;176(3):535-548.e24. doi:10.1016/j.cell.2018.12.015
606 607 608	57.	Payne A, Holmes N, Clarke T, Munro R, Debebe BJ, Loose M. Readfish enables targeted nanopore sequencing of gigabase-sized genomes. <i>Nat Biotechnol.</i> 2021;39(4):442-450. doi:10.1038/s41587-020-00746-x
609 610 611	58.	Stevanovski I, Chintalaphani SR, Gamaarachchi H, et al. Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. <i>Sci Adv.</i> 2022;8(9). doi:10.1126/SCIADV.ABM5386
612 613 614	59.	Gamaarachchi H, Samarakoon H, Jenner SP, et al. Fast nanopore sequencing data analysis with SLOW5. <i>Nat Biotechnol</i> . 2022;40(7):1026-1029. doi:10.1038/s41587-021-01147-4
615 616 617	60.	Samarakoon H, Ferguson JM, Jenner SP, et al. Flexible and efficient handling of nanopore sequencing signal data with slow5tools. <i>Genome Biol</i> . 2023;24(1):69. doi:10.1186/s13059-023-02910-3
618 619	61.	Li H. Minimap2: pairwise alignment for nucleotide sequences. <i>Bioinformatics</i> . 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
620 621 622	62.	Zheng Z, Li S, Su J, Leung AWS, Lam TW, Luo R. Symphonizing pileup and full- alignment for deep learning-based long-read variant calling. <i>Nat Comput Sci</i> . 2022;2(12):797-803. doi:10.1038/s43588-022-00387-x

623 624	63.	Martin M, Patterson M, Garg S, et al. WhatsHap: fast and accurate read-based phasing. Published online 2016. doi:10.1101/085050
625 626	64.	Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative Genomics Viewer. <i>Nat Biotechnol</i> . 2011;29(1):24. doi:10.1038/NBT.1754
627 628 629	65.	Zeng Z, Bromberg Y. Predicting Functional Effects of Synonymous Variants: A Systematic Review and Perspectives. <i>Front Genet</i> . 2019;0:914. doi:10.3389/FGENE.2019.00914
630 631 632 633 634 635	66.	Kishore Jaganathan A, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning In Brief A deep neural network precisely models mRNA splicing from a genomic sequence and accurately predicts noncoding cryptic splice mutations in patients with rare genetic diseases. Predicting Splicing from Primary Sequence with Deep Learning. <i>Cell</i> . 2018;176:535-548. doi:10.1016/j.cell.2018.12.015
636 637 638	67.	Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. <i>Nucleic Acids Res.</i> 2001;29(1):308-311. Accessed March 5, 2019. http://www.ncbi.nlm.nih.gov/pubmed/11125122
639 640 641	68.	Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using variation in 76,156 human genomes. <i>Nature</i> . 2024;625(7993):92-100. doi:10.1038/s41586-023-06045-0
642 643	69.	All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The "All of Us" Research Program. <i>N Engl J Med</i> . 2019;381(7):668-676. doi:10.1056/NEJMsr1809937
644 645 646	70.	Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. <i>Nature</i> . 2021;590(7845):290-299. doi:10.1038/s41586-021-03205-y
647 648	71.	Kent WJ. <tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool. <i>Genome</i> <i>Res</i> . 2002;12(4):656-664. doi:10.1101/gr.229202
649 650	72.	Castle JC. SNPs occur in regions with less genomic sequence conservation. <i>PLoS One</i> . 2011;6(6):e20660. doi:10.1371/journal.pone.0020660
651 652 653	73.	Boisson M, Arrondel C, Cagnard N, et al. A wave of deep intronic mutations in X- linked Alport syndrome. <i>Kidney Int.</i> 2023;104(2):367-377. doi:10.1016/j.kint.2023.05.006
654 655 656	74.	Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a Large Cohort of Patients With Inherited Retinal Diseases. <i>Front Genet</i> . 2021;12:647400. doi:10.3389/fgene.2021.647400
657 658 659 660	75.	Di Scipio M, Tavares E, Deshmukh S, et al. Phenotype Driven Analysis of Whole Genome Sequencing Identifies Deep Intronic Variants that Cause Retinal Dystrophies by Aberrant Exonization. <i>Invest Ophthalmol Vis Sci</i> . 2020;61(10):36. doi:10.1167/iovs.61.10.36

661 662 663	76.	Xie Z, Sun C, Liu Y, et al. Practical approach to the genetic diagnosis of unsolved dystrophinopathies: a stepwise strategy in the genomic era. <i>J Med Genet</i> . 2021;58(11):743-751. doi:10.1136/jmedgenet-2020-107113
664 665 666	77.	Zaum AK, Stüve B, Gehrig A, et al. Deep intronic variants introduce DMD pseudoexon in patient with muscular dystrophy. <i>Neuromuscul Disord</i> . 2017;27(7):631-634. doi:10.1016/j.nmd.2017.04.003
667 668 669	78.	Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. <i>J Appl Genet</i> . 2018;59(3):253-268. doi:10.1007/s13353-018-0444-7
670 671 672 673	79.	Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <i>Genetics in Medicine</i> . 2015;17(5):405-424. doi:10.1038/gim.2015.30
674 675 676	80.	Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43). <i>Neurol Genet</i> . 2016;2(5):e94. doi:10.1212/NXG.00000000000094
677 678 679	81.	Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching oligonucleotide therapy. <i>Nature</i> . 2023;619(7971):828-836. doi:10.1038/s41586-023-06277-0
680 681 682	82.	Chen S, Heendeniya SN, Le BT, et al. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases. <i>BioDrugs</i> . 2024;38(2):177-203. doi:10.1007/s40259-024-00644-7
683 684 685	83.	Santos JI, Gonçalves M, Matos L, et al. Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example. <i>Life</i> . 2022;12(5):608. doi:10.3390/life12050608
686 687 688	84.	Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. <i>Ann Neurol</i> . 2013;74(5):637-647. doi:10.1002/ana.23982
689 690 691	85.	Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. <i>Neurology</i> . 2020;94(21):e2270-e2282. doi:10.1212/WNL.00000000009233
692 693	86.	Heo YA. Golodirsen: First Approval. <i>Drugs</i> . 2020;80(3):329-333. doi:10.1007/s40265-020-01267-2
694 695 696 697	87.	Clemens PR, Rao VK, Connolly AM, et al. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. <i>JAMA Neurol</i> . 2020;77(8):982-991. doi:10.1001/jamaneurol.2020.1264
698 699	88.	Shirley M. Casimersen: First Approval. <i>Drugs</i> . 2021;81(7):875-879. doi:10.1007/s40265-021-01512-2

700 701 702	89.	Wurster CD, Winter B, Wollinsky K, et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. <i>J Neurol</i> . 2019;266(1):183-194. doi:10.1007/s00415-018-9124-0
703 704 705	90.	Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. <i>Eur J Paediatr Neurol</i> . 2021;30:1-8. doi:10.1016/j.ejpn.2020.11.004
706 707 708	91.	Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later- Onset Spinal Muscular Atrophy. <i>N Engl J Med.</i> 2018;378(7):625-635. doi:10.1056/NEJMoa1710504
709 710 711	92.	Bianchi L, Sframeli M, Vantaggiato L, et al. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. <i>Int J Mol</i> <i>Sci.</i> 2021;22(9). doi:10.3390/ijms22094329
712 713 714	93.	Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching oligonucleotide therapy. <i>Nature</i> . 2023;619(7971):828-836. doi:10.1038/s41586-023-06277-0
715 716 717	94.	Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. <i>N Engl J Med.</i> 2019;381(17):1644-1652. doi:10.1056/NEJMoa1813279
718 719 720	95.	Yamada M, Maeta K, Suzuki H, et al. Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration. <i>Sci Rep.</i> 2024;14(1):6506. doi:10.1038/s41598-024-56704-z
721 722 723	96.	Aguti S, Bolduc V, Ala P, et al. Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD. <i>Mol Ther</i> <i>Nucleic Acids</i> . 2020;21:205-216. doi:10.1016/J.OMTN.2020.05.029
724 725 726	97.	Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. <i>N Engl J Med</i> . 2019;381(17):1644-1652. doi:10.1056/NEJMOA1813279
727 728 729	98.	Dominov JA, Uyan Ö, McKenna I Yasek D, et al. Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. <i>Ann Clin Transl Neurol</i> . 2019;6(4):642-654. doi:10.1002/acn3.738
730 731 732	99.	Martínez-Pizarro A, Leal F, Holm LL, et al. Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene. <i>Nucleic Acid Ther</i> . 2022;32(5):378-390. doi:10.1089/nat.2021.0066
733		

Family #	Family 1				Family 2
Individual	V:1	V:3	V:4	V:6	II:1
Sex	M	F	M	M	F
Onset	Fourth decade	Childhood	Childhood	Childhood	Early-adult
Age at evaluation	60-65	65-70	65-70	65-70	50-55
(years)					
Presenting symptom	Gait unsteadiness	Difficulty running	Difficulty sitting on crossed	Difficulty running,	Bilateral leg weakness
			legs during childhood	multiple ankle sprains	and sensory disturbance
Atrophy UL/LL	Yes/yes	Yes/yes	Yes/yes	Yes/yes	No/Yes
					(left calf only)
Foot deformity	None	Pes cavus/hammer toes	-	Pes cavus	Pes cavus
Tone UL/LL	Normal/reduced	Normal/normal	Normal, increased		Normal/normal
Shoulder abduction	5	5	3	5	4
Elbow flexion	4	5	3	4	5
Elbow extension	4	5	3	4	5

Table 1. Phenotypic characterization of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations- AFO: Ankle foot orthoses; CMTNS: Charcot-Marie-Tooth Neuropathy Score; UL/LL: Upper Limb/Lower Limb

			<u>.</u>		•
Finger abduction	2	4	3	1	4
Hip flexion	4	3	3	3	4
Knee extension	4	3	3	4	4
Knee flexion	4	3	3	4	4
Ankle dorsiflexion	0	0	3	1	3
Ankle plantarflexion	0	0	3	0	4
Deep tendon	Absent/absent	Absent ankle	Hyperreflexia knee, absent	Absent/absent	Normal/ reduced ankle
reflexes UL/LL			ankle		reflexes
Plantars	Absent	-	Absent	Flexor	Flexor
Proprioception	Normal/reduced to	-	-	Normal/reduced to the	Normal/reduced to ankle
UL/LL	the MTP			ankle	
Vibration UL/LL	Normal/reduced to	Absent in toes	-	Reduced to	Reduced to mid-shin
	ankle			wrist/reduced to knees	
Pinprick UL/LL	Normal/reduced to	Normal/reduced to the	Reduced to elbows/reduced	Reduced to PIP	Reduced to mid-shin
	ankle	mid shin	to knees	joint/reduced to knees	Reduced dorsum hand
Temperature	Normal/reduced to	-	-	Reduced to	Reduced to mid-shin
sensation UL/LL	ankle			wrist/reduced to above	

				knee	
Other	Cough	GORD and cough	Corticospinal tract signs	Nil	Fatty infiltration on left
symptoms/signs					gastrocnemius
Gait	High steppage/ataxic	High steppage/ataxic	Steppage gait	High steppage/ataxic	High steppage
Romberg's sign	Positive	Positive		Positive	Mild sway
Mobility aids	AFO, walking stick	AFO, walker	AFO, walker, mobility	Wheelchair	AFO, elbow crutch
	and mobility scooter		scooter		
CMTNS (version 2)	31	-	28/36	36	15

Table 2. Nerve conduction study (NCS) findings of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations: APB: abductor pollicis brevis; ADM: abductor digiti minimi; EDB: extensor hallucis brevis; FHB: flexor hallus brevis; CMAP: compound motor action potential; CV: conduction velocity; NR: no response; SNAP: sensory nerve action potential; R: right, L:left.

Family #	Family 1		Family 2	
Individual	V:1	V:6	II:1	
Age at NCS (years)	60-65	65-70	55-60	
Median nerve (digit II) [orthodromic(F	[?)]			
SNAP (uV)	NR	NR	6.6	
CV (m/s)	NR	NR	50	
Ulnar nerve (digit V) [orthodromic(R)]			
SNAP (uV)	NR	1	4.9	
CV (m/s)	NR	40.2	51	
Sural nerve [orthodromic(R)]	1	1	1	
SNAP (uV)	NR	NR	NR	
CV (m/s)	NR	NR	NR	
Sural nerve [orthodromic(L)]	I	1	I	

SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Median nerve (APB) (R)		1	1
CMAP (mV)	NR	NR	4.8
CV (m/s)	NR	NR	41
Ulnar nerve (ADM) (R)		1	1
CMAP (mV)	2	0.6	6.6
CV (m/s)	44.4	44.7	52 (wrist-below elbow)
			57 (wrist-above elbow)
Peroneal nerve (EDB) (R)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Tibial nerve (FHB) (L)		1	1
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Needle EMG	Absent voluntary units in the right tibilias anterior and medial gastrocnemius muscles, as well as denervation-reinnervation changes in	Absent recruitment of motor units in the right tibialis anterior, medical gastrocnemius, first dorsal interosseous and vastus lateralis	Reduced recruitment of motor units in the right tibialis interior and right vastus medialis muscles. Discrete recruitment of muscle fibres in the

the right vastus lateralis muscle.	muscles. Denervation-reinnervation	right gastrocnemius muscle.
	changes were evident in the right	
	deltoid, biceps brachii and triceps	
	brachii muscles.	





